Ivabradine: a preliminary observation for a new terapeutic role in patients with multiple organ dysfunction syndrome
Open Access
- 8 May 2014
- journal article
- letter
- Published by Springer Science and Business Media LLC in Clinical Research in Cardiology
- Vol. 103 (10), 831-834
- https://doi.org/10.1007/s00392-014-0722-2
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCENDClinical Research in Cardiology, 2013
- Ivabradine: potential clinical applications in critically ill patientsClinical Research in Cardiology, 2012
- Temporal trends in patient characteristics and survival of intensive care admissions with sepsisCritical Care Medicine, 2012
- Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational studyClinical Research in Cardiology, 2011
- Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I f (funny channel current) inhibitor ivabradineClinical Research in Cardiology, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgeryClinical Research in Cardiology, 2010
- Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Mechanisms of sepsis-induced cardiac dysfunctionCritical Care Medicine, 2007
- Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications*Critical Care Medicine, 2005